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ABSTRACT 24 
Central nervous system (CNS) drug delivery is often hampered due to the insidious nature of 25 
the blood-brain barrier (BBB).  Nose-to-brain delivery via olfactory pathways have become a 26 
target of attention for drug delivery due to bypassing of the BBB.  The antioxidant properties 27 
of phytochemicals make them promising as CNS active agents but possess poor water 28 
solubility and limited BBB penetration. The primary aim of this study was the development 29 
of mesoporous silica nanoparticles (MSNs) loaded with the poorly water-soluble 30 
phytochemicals curcumin and chrysin which could be utilised for nose-to-brain delivery.  We 31 
formulated spherical MSNP using a templating approach resulting in ~220 nm particles with 32 
a high surface porosity. Curcumin and chrysin were successfully loaded into MSNP and 33 
confirmed through Fourier transformation infrared spectroscopy (FT-IR), differential 34 
scanning calorimetry (DSC), thermogravimetric analysis (TGA) and HPLC approaches with 35 
a loading of 11-14% for curcumin and chrysin.  Release was pH dependant with curcumin 36 
demonstrating increased chemical stability at a lower pH (5.5) with a release of 53.2 % ± 2.2 37 
% over 24 hours and 9.4 ± 0.6 % for chrysin.  MSNP were demonstrated to be non-toxic to 38 
olfactory neuroblastoma cells OBGF400, with chrysin (100 µM) demonstrating a decrease in 39 
cell viability  to 58.2 ± 8.5 % and curcumin an IC50 of 33 ± 0.18 µM.  Furthermore confocal 40 
microscopy demonstrated nanoparticles of < 500nm were able to accumulate within cells 41 
with FITC-loaded MSNP showing membrane localised and cytoplasmic accumulation 42 
following a 2-hour incubation. MSNP are useful carriers for poorly soluble phytochemicals 43 
and provide a novel vehicle to target and deliver drugs into the CNS and bypass the BBB 44 
through olfactory drug delivery. 45 
  46 
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1. INTRODUCTION 49 
The World Health Organisation (WHO) have highlighted that neurological disorders are one 50 
of the biggest threats to public health 
1
. Disorders of the CNS account for approximately 1 % 51 
of deaths but this is associated with a worldwide disease burden of almost 11 %, and it is 52 
thought that approximately 1.5 billion people worldwide suffer from some kind of brain or 53 
CNS disorder 
1
.   Furthermore with an increasingly ageing population, by the year 2020 one 54 
in every three people alive will suffer from a central nervous system (CNS) related disorder 
1
.  55 
Similar paradigms exist within the pharmaceutical industry with less than 8 % of CNS-56 
indicated drugs successfully enter clinical trials and accompanied by an overall drop in the 57 
success rate of delivering a candidate to market 
2
, with the US Food and Drug Administration 58 
(FDA) only approving between 15-25 new compounds per year 
2
.  Despite advances in drug 59 
delivery technologies, CNS drug targeting and delivery is still a limiting factor with less than 60 
1 % of all CNS-targeted compounds showing activity against CNS diseases 
3, 4
.  This is 61 
despite many of these compounds possessing physicochemical properties that would 62 
normally predispose them to good membrane permeability (e.g, molecular weight < 500 and 63 
highly lipid soluble) 
5
.  The brain is a very highly vascularised organ with a microvascular 64 
surface area of 150-200 cm
2
 g. tissue (12-18 m
2
) in humans 
6
.  However, the primary cause of 65 
poor brain deposition of therapeutics is often associated with an impermeable barrier termed 66 
the blood-brain barrier (BBB), formed from brain microvascular endothelial cells and which 67 
are highly selective in controlling the entry of endogenous and exogenous compounds into 68 
the brain. 69 
The development of CNS disorders is often associated with the process of oxidative stress 70 
and leads to a range of neurological disorders such as epilepsy 
7, Alzheimer’s disease and 71 
dementia 
8
.  However, a novel category of potential therapeutic agents possessing anti-72 
oxidant activities are phytochemicals, which are derived from natural extracts from plants.  73 
Over 8000 compounds have been identified as belonging to the general category of 74 
polyphenols 
9
 of which flavonoids are a major class and contributing over 6500 distinct 75 
compounds 
10
. 76 
Many phytochemicals have been reported to possess CNS indicating effects including the 77 
protection of neurons from neurotoxins and neuro-inflammation in degenerative diseases 
11-
78 
17
.  Furthermore, an increasing body of clinical evidence is supporting the view that 79 
flavonoids impart a protective function towards dopamine neurons through the prevention of 80 
oxidative damage and apoptosis 
18, 19
.  The target site for flavonoids is thought to be 81 
widespread within the CNS, but much attention has been focussed on the ability of 82 
phytochemicals to interact with the GABAA receptor, one of the most important 83 
neurotransmitter sites within the CNS.  Indeed, many phytochemicals demonstrated 84 
significant inhibitory actions on GABAA in low micromolar concentration, e.g. chrysin (3 85 
µM) 
20
 and 6-methylapigenin (495 nM) 
21
.  Furthermore, chrysin has been demonstrated to 86 
result in anxiolytic in mice at an intraperitoneal dose of 1 mg/kg 
22
.  In addition to their action 87 
on receptor sites, a range of phytochemicals have been demonstrated to modulate the genome 88 
and proteome of the promiscuous network of membrane transporter proteins localised at the 89 
BBB 
23
. 90 
Phytochemical flavonoids are therefore a potentially novel multi-faceted class of molecules 91 
which show potential for a range of CNS patho-physiologies 
24-36
. However, many 92 
phytochemicals are poorly soluble and are not immediately amenable to direct formulation 93 
into dosage forms for oral/transdermal or parenteral systems.  94 
 95 
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Many groups have demonstrated successful loading and delivery of phytochemicals using 96 
nanoparticle carrier systems to enhance their solubility and delivery, with the most commonly 97 
studied phytochemical being curcumin 
37-40
 and chrysin 
41, 42, 43
 98 
A class of biocompatible nanomaterials that has gained attention for drug delivery are 99 
mesoporous silica nanoparticles (MSNP).  Silica is biocompatible and is often used in 100 
inorganic nanoparticles 
44, 45
.  Silica nanoparticles are highly porous in nature, with the pore 101 
sizes, density and total surface area being highly tuneable making them excellent tools for 102 
biomolecule detection, drug delivery systems and for contrast agent protectors 
46-48
. 103 
Mesoporous material was first discovered by Mobil Corporation in 1992 
49
 and termed 104 
MCM-41, possessing a honeycomb-like porous structure with hundreds of pore channels 105 
(termed mesopores) that have the potential to absorb molecules . This results in mesoporous 106 
nanoparticles having a high surface area (> 900 m
2
/g), large pore volume (> 0.9 cm
3
/g) with 107 
the added benefit of a tuneable pore size over a very narrow size distribution (2–10 nm) 50.  108 
Furthermore, mesoporous silica nanoparticles have recently been used to demonstrate loading 109 
and release of curcumin 
51
.  110 
To overcome the difficulties associated with crossing the BBB, approaches at bypassing the 111 
BBB have more recently focused on exploiting the olfactory mucosa within the nasal cavity, 112 
by virtue of the fact that olfactory neurones are directly exposed to the external environment 113 
52, 53
 and provide a direct pathway to the olfactory bulb and brain. This regions covers the 114 
upper part of the nasal cavity with an approximate surface area of 2.5-10 cm
2
 in humans  
54
.  115 
It is primarily comprised of approximately 12 million olfactory receptor cells 
55
. The 116 
olfactory region has been the focus of one of the major ‘nose-to-brain’ pathways to deliver 117 
drugs directly to the brain through olfacotry deposition. The first recorded success in the 118 
delivery of a therapeutic agent into the brain in humans, following IN administration, was in 119 
a patent application by William Frey II 
56, 57
 reporting the successful delivery of neurological 120 
agents and macromolecules (insulin) 
58
 targeting Alzheimer’s disease. These reports 121 
established a novel approach to target CNS drug delivery through potential bypassing of the 122 
BBB, and is particularly attractive as the targeted delivery onto the olfactory mucosa (as 123 
opposed to parenteral delivery) would require reduced drug loaded requirements. 124 
Given the relative ease of preparation of MSNP and the tuneable nature of the nanomaterials, 125 
MSNP are an interesting group of nanoparticles which have not fully been exploited for nose-126 
to-brain delivery. The aim of this study is to investigate the use of MSNP as carriers for the 127 
poorly soluble phytochemicals curcumin and chrysin, which are known to possess CNS 128 
pharmacological action 
59-68
, and to assess their loading capacity and release profile along 129 
with the cellular compatibility and in-vitro uptake into cultured olfactory cells. 130 
 131 
2. MATERIALS AND METHODS 132 
2.1 Materials 133 
Dulbecco’s Modified Eagle Medium (MEM), Dulbecco’s Modified Medium: Nutrient 134 
Mixture F12 (DMEM-F12), Dulbecco’s Phosphate buffered saline (PBS), L-glutamine 135 
200mM, non-essential amino acids (NEAA), penicillin/streptomycin and trypsin-EDTA 136 
solution were obtained from PAA laboratories (Austria); foetal bovine serum (FBS) (Labtech, 137 
Essex, UK); potassium chloride, magnesium sulphate, calcium chloride, acetonitrile, 138 
orthophosphoric acid, acetic acid, ethanol, sodium hydroxide, and sodium chloride were 139 
obtained from Fisher Scientific (Loughborough, UK); acutase (Biolegend, UK); gentamycin, 140 
cetyl trimethylammonium bromide (CTAB), tetraethoxy orthosilicate (TEOS),  (3-(4, 5-141 
dimethylthiazol-2-yl)-2, 5-diphenyl Tetrazolium bromide) MTT, trypan blue, dimethyl 142 
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sulfoxide (DMSO),  potassium phosphate, ammonium hydroxide, rhodamine 6G, fluorescein 143 
isothiocynate (FITC),DAPI, collagen, cell culture water, monobasic were obtained from 144 
Sigma-Aldrich (Dorset, UK). 145 
2.2 Methods 146 
2.2.1 Preparation of MSNP 147 
MSNP were prepared using a modified method described by Fan et al 
69
.  Briefly, 1.0 g of 148 
CTAB (2.74 mmol) was dissolved in 480 mL distilled water. Thereafter 3.5 mL of aqueous 149 
sodium hydroxide solution (2 M) was added and the temperature of the mixture was raised to 150 
80 °C. 5 mL TEOS (22.4 mmol) was then introduced drop wise into the reaction mixture 151 
whilst stirring vigorously for two hours until a white precipitate was formed. The precipitate 152 
was then filtered and washed with distilled water and methanol and dried under vacuum. The 153 
surfactant template (CTAB) was removed by refluxing 1.5 g of the synthesized silica 154 
particles with 1.5 mL of hydrochloric acid (37.2 % w/v) and 150 mL methanol for 6 hours. 155 
The product was washed extensively with distilled water and methanol. The surfactant free 156 
silica particles were placed under high vacuum with heating at 60°C to remove the remaining 157 
solvent from the mesopores.  158 
2.2.2 Size and zeta-potential 159 
The size and zeta potential (ζ) of MSNPs were determined using dynamic light scattering 160 
techniques through the use of a NanoBrook 90 Plus Zeta (Brookhaven Instruments 161 
Corporation).  100 µL of 1 mg/mL sonicated MSNPs suspension was added to 3 mL 162 
ultrapure water, vortexed and used to measure the particles size. The mean diameter was 163 
obtained from 3 runs of 3 minutes. The polydispersity index (PDI) was used to indicate the 164 
particle size distribution within the sample.  The zeta potential is an indicator for charge 165 
present on the surface of nanoparticles, which is responsible for the stability of formulation 166 
and interaction with cellular membranes. The zeta potential of nanoparticles is measured 167 
using the principle of electrophoretic mobility under an electric field. The average of 3 168 
readings (each reading = 30 runs) was reported. The temperature was maintained at 25°C 169 
during the measurements. 170 
2.2.3 SEM 171 
Samples of MSNP were mounted on 12 mm aluminium pin stubs with 12 mm carbon tabs 172 
and coated with 15nm of gold. The powders were imaged at 5 kV with a 150 pA beam in 173 
high vacuum due to beam damage to the samples at higher kV’s. The nanoparticles were 174 
imaged at 10 kV with a 100 pA beam also in high vacuum using a Carl Zeiss EVO LS 15 175 
with a Quorum QR105S gold coater. 176 
 177 
2.2.4 Nitrogen absorption-desorption 178 
The specific surface areas of the blank MSNPs were analysed using the Brunauer–Emmet–179 
Teller (BET) method 
70
 using a Quantchrome NOVA (Quantchrom, Finland). The analysis 180 
was based on the amount of Nitrogen (N2) gas adsorbed at various partial pressures (P/P0) 181 
between 0.05 and 0.3. Before N2 adsorption, samples were degassed under vacuum at a 182 
temperature of 100° C. The nitrogen molecular cross sectional area (0.162 nm
2
) was used to 183 
determine the surface area. The pore size distribution and total pore volume was determined 184 
by using density functional theory (DFT) method.  All calculations were software automated 185 
(Quantchrome NOVAWIN, Quantchrom, Finland). 186 
 187 
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2.2.5 TGA 188 
Thermal stability analysis of the functionalized silica was performed by thermogravimetric 189 
analysis (TGA) using a Pyris 1 TGA (Perkin Elmer) instrument. 3 mg of MSNP materials 190 
were analyzed under nitrogen purge with a starting temperature of 35 °C and 10 °C/min ramp 191 
rate to 800 °C. The corresponding carbon, hydrogen and nitrogen elemental analysis was 192 
performed using a LECO CHN-2000 elemental analyzer under flowing oxygen. 193 
2.2.6 DSC 194 
Heating curves of MSNP were obtained using differential scanning calorimeter (DSC Q200, 195 
TA instruments, Delware). Samples were weighed and 2-5 mg were loaded into a non-196 
hermetically crimped aluminium pan and heated under a nitrogen purge at the rate 50 197 
mL/min. Samples were heated from 30 to 350°C at the heating rate 10°C/min under nitrogen. 198 
Data was analysed using Universal Analysis 2000 software V4.5A TA instruments. 199 
2.2.7 FT-IR 200 
MSNP were further characterised by using FT-IR techniques for the bare MSNPs, and drug 201 
loaded MSNPs. FT-IR absorbance was collected using a Nicolet iS5 FT-IR 202 
spectrophotometer (Thermo Scientific,USA) over the spectral range of 550-4000 cm
-1
.  203 
2.2.8 Phytochemical loading 204 
Chrysin: 20 mg/mL chrysin was dissolved in DMF and in a separate vial 20 mg/mL of 205 
MSNPs were dispersed in DMF and bath sonicated for 15 minutes. A volume of 1 mL from 206 
each vial was combined and resulted in a final concentration of 10 mg/mL of both chrysin 207 
and MSNP. The glass vial was sealed and covered with foil, sonicated for 15 minutes in a 208 
water sonicating bath and left for stirring at 100 rpm at room temperature. After 24 hours the 209 
vial contents was filtered through a 0.22 µm cellulosic white membrane filter (MSI Micron 210 
Separations Inc., USA). Chrysin loaded MSNP were termed ‘Chry-MSNP’. 211 
Curcumin: 20 mg/mL curcumin was dissolved in a 30:70 mixture acetone:ethanol and 212 
processed as described above.  Curcumin loaded MSNP were termed ‘Curc-MSNP’. 213 
 214 
The filtrate was collected to determine the loading (entrapment efficiency) and this approach 215 
was termed the ‘wet’ approach. The entrapment efficiency (EE) was calculated based on the 216 
following formula: 217 
       
                                          
              
                
where HPLC-UV methods were used to assess content. 218 
 219 
The loaded nanoparticles collected on the filter paper were dried under high vacuum for 2 220 
days, washed with PBS to remove superficially adsorbed phytochemicals and loading was 221 
assessed through TGA.  This approach was termed the ‘dry’ approach, where the loading 222 
content (LC) was calculated from the difference between the final weight loss for MSNP and 223 
phytochemical loaded MSNP at the end of the heating cycle and derived from data obtain 224 
from TGA analysis.  225 
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Confirmation of phytochemical loading was further determined using HPLC-UV, DSC, 226 
TGA, FT-IR and DLS/zeta potential analysis.  227 
2.2.9 Cellular toxicity towards olfactory cells: MTT assay  228 
To assess the compatibility between formulation and olfactory mucosa type cells, the porcine 229 
olfactory bulb neuroblastoma cell line OBGF400 was used as an in-vitro cell culture model of 230 
the olfactory cells/mucosa 
71
.  OBGF400 cells are bipolar to multipolar in nature with 231 
prominent cell bodies and a distinctive nucleus and extending axonal structures confirm as 232 
neuronal cells.  233 
OBGF400 were a kind gift from Dr. Gail Scherba (University of Illinois, USA) and were 234 
grown in DMEM/F-12 (Dulbecco’s Modified Medium: Nutrient Mixture F12) supplemented 235 
with sodium bicarbonate, HEPES, gentamicin (50 µg/mL), penicillin G/streptomycin, bovine 236 
calf serum (BCS) in a humidified 37°C incubator with 5% CO2.  At 80-90 % confluency, the 237 
media was aspirated and cells were treated with Acutase
®
 for 20-30 minutes prior to 238 
passaging. 239 
Cells were seeded into 96-well plates at a density of 1x10
4
 cells per well. Cells were 240 
subsequently exposed to 10-1000 µg/mL MSNPs for 24 hours at 37 °C and 5 % CO2 241 
humidified environment and cellular toxicity was assessed using a 3-(4,5-Dimethylthiazol-2-242 
yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay.  Briefly, following incubation the media 243 
was removed and replaced with 100 µL of media containing 0.5 mg/mL MTT dissolved in 244 
PBS and incubated at 37 °C in an air humidified environment for 4 hours. Thereafter, the 245 
media was removed and 100 µL of DMSO was added and the plates left to incubate for 15 246 
minutes in the dark. The UV-absorbance of the formazan product was determined at 595 nm.  247 
The UV-absorbance of the formazan product was measured on a multi-plate reader (Bio-Rad 248 
laboratories, Hercules, CA) using 570 nm as a test wavelength and 600 nm as a reference 249 
wavelength.  The mean of the blank UV-absorbance was subtracted from the UV-absorbance 250 
of each controls and samples and percentage viability was calculated as follows: 251 
                 
                    
                      
                    252 
 253 
The cellular viability IC50 was subsequently calculated using a sigmoidal dose response 254 
function. Each concentration was assayed in eight wells and run in three independent 255 
experiments and results expressed as percentage cytotoxicity relative to a control (0.5% 256 
DMSO).  257 
The cellular toxicity of curcumin and chrysin were also assessed using OBGF 400 cells at a 258 
concentration range of 0.01-50,000 µM, as described above.  The cell viability was calculated 259 
by comparing the absorbance of phytochemical or drug treated well to that of control well. 260 
2.2.10 Cellular toxicity towards olfactory cells: Live cell imaging  261 
To assess the morphological alterations in cellular structures when exposed to MSNP, Curc-262 
MSNP and Chry-MSNP, live cell imaging of OBGF400 was conducted over a 40-hour period 263 
in an oxygen, CO2 and humidity controlled phase contrast imaging systems (CellIQ
®
, Chip-264 
Man Technologies, Tampere, Finland).  OBGF400 cells were seeded into wells of a 6-well 265 
plate at a density of 5x10
5
 cells/well and allowed to adhere and proliferate to 70 % 266 
confluence.  Subsequently wells were washed with warm HEPES (25 mM) buffered HBSS, 267 
followed by the addition of 50-150 µg/mL of MSNP, Curc-MSNP and Chry-MSNP dispersed 268 
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in maintenance media for 40 hours with images captured within a defined window within 269 
each well every 15 minutes using live-cell imaging and presented as images. 270 
2.2.11 Cellular uptake of nanoparticles into olfactory cells 271 
Coverslips were sterilised in 70% ethanol for 30 minutes, dried in a laminar air hood and 272 
coated with 6 µg/cm
2
 of a collagen prepared in sterile water from a 0.1 % w/v (0.1 M acetic 273 
acid) stock solution, with coating taking place in 12-well plates.  Plates were left to dry in the 274 
laminar air flow for 2 hours.  Excess collagen was then removed and coverslips washed with 275 
sterile water and left for drying.   Thereafter cell suspensions of OBGF 400 cells were seeded 276 
at a density of 1x10
5
 cells/cm
2
 into wells of a 12 well plate containing the coated coverslips 277 
and left to adhere and proliferate to a confluency of approximately 70% in a 5% CO2 278 
humidified incubator.   279 
To identify the optimal particle size range for olfactory uptake, fluorescent latex beads 280 
(carboxylate modified) of 100 nm (λex ~491 nm; λem ~521 nm) and 500 nm (λex ~575 nm; 281 
λem ~610 nm) were initially utilised as a rapid fluorescence-based screening tool to consider 282 
the boundary range of 100-500 nm for nanoparticle uptake into OBGF400 cells.  Fluorescent 283 
latex beads were dispersed into HEPES (25mM) buffered HBSS at a concentration of 0.1 % 284 
v/v and sonicated for 10 minutes in a water-bath sonicator prior to the addition into wells. 285 
Subsequently, to assess the cellular uptake of formulated MSNP (section 2.2.1), FITC was 286 
passively loaded into MSNP (see supplementary materials section 1), dispersed into HEPES 287 
(25mM) buffered HBSS at a concentration of 0.1 % v/v and sonicated for 10 minutes in a 288 
water-bath sonicator prior to the addition into wells 289 
Coverslips were incubated for 2 hours in a 5 % CO2 humidified incubator before being 290 
washed with ice cold HEPES (25mM) buffered HBSS and fixed with 4 % w/v 291 
paraformaldehyde for 30 minutes in the dark.  The coverslips were then mounted onto glass 292 
slides with mounting media containing 4',6-diamidino-2-phenylindole (DAPI). The 293 
localisation of the latex beads was analysed using an upright confocal microscope (Leica SP5 294 
TCS II MP) and visualised with a 40x oil immersion objective. All images were acquired 295 
using an argon laser at 494 nm or DPSS 561 laser at 561 nm to visualise beads/MSNP and a 296 
helium laser to visualise DAPI at 461 nm. 297 
2.2.12 HPLC detection of phytochemicals 298 
The detection of curcumin was based on an adapted method previously reported by Li et al 
72
.  299 
An Agilent 1200 Series (Waldbronn, Germany) equipped with a multiple wavelength detector 300 
(MWD) and a Phenomenex Luna C18 (150 × 4.6 mm) 5 µm column was used for RP-HPLC. 301 
The mobile phase was prepared using ACN:5% acetic acid in a ratio of 45: 55 (v/v). Mobile 302 
phases were filtered through a 0.45 µm filter and sonicated before use. The ﬂow rate was 303 
maintained at 0.8 mL/min with a 15 minutes run time and injection volume of 20 µL, while 304 
column temperature was mainlined at ambient temperatures. Calibration curves were 305 
constructed using standard solutions of known concentrations from 5 to 50 µg/mL. The 306 
software used for data collection, analysis and control of the system was ChemStation 307 
Version 1.24 SP1.   The UV detection of curcumin was measured at 420 nm.  308 
An RP-HPLC method was used to quantify chrysin 
73
. The same HPLC system described 309 
above was used to analyse chrysin samples.  The mobile phase comprised of 310 
water:methanol:acetonitrile:phosphoric acid in a ratio of 60:30:38:1 (v/v). Mobile phases 311 
were filtered through 0.45 µm filter and sonicated before use. The ﬂow rate was maintained 312 
at 1.0 mL/min with 17 minutes run time and the injection volume was 10 µL while column 313 
temperature was kept at ambient temperatures. Calibration curves were constructed using 314 
10 
 
standard solutions of known concentrations from 0.78 to 10,000 µg/mL. The UV detection of 315 
chrysin was measured at 262 nm. 316 
 317 
2.2.13 Release of phytochemicals from MSNP 318 
To assess the in-vitro release of curcumin and chrysin from MSNPs, studies were performed 319 
in phosphate buffered saline (154 mM PBS pH 7.4) containing 0.1 % Tween 80.  320 
Phytochemical loaded MSNP, 2 mg, were dispersed into 2 mL of release medium, briefly 321 
sonicated and placed in a shaking incubator maintained at 37 ˚C and 100 rpm. Samples were 322 
withdrawn at set time intervals and the volume replaced with an equal volume of pre-warmed 323 
release medium. The release of phytochemicals was assessed through HPLC-UV methods. 324 
Throughout the release studies Tween 80 was used to maintain the sink conditions and also to 325 
dissolve curcumin in the release medium 
74
. The results were calculated in terms of 326 
cumulative release (% w/w) relative to actual entrapped weight of curcumin or chrysin in the 327 
MSNPs.  To assess the impact of pH on drug release, release studies were also conducted at 328 
pH 5.5 (average nasal pH). 329 
2.2.14 Statistical analysis 330 
Unless otherwise stated, three independent experiments were carried out for each study. 331 
Statistical significance was evaluated by one-way ANOVA or paired two-tail Students t-test 332 
using GraphPad Prism version 6.00 (GraphPad Software, La Jolla California USA, 333 
www.graphpad.com). Unless otherwise stated, data is reported as mean ± standard deviation 334 
(SD). A significance level (P-value) of < 0.05 was considered as statistically significant. 335 
 336 
3. RESULTS AND DISCUSSION 337 
3.1 MSNP formulation and characterisation 338 
MSNP were formulated according to the methods described by Fan et al 
69
, which employs a 339 
templating approach where template removal determines the hollow interior of the MSNP.  340 
During the formation CTAB is responsible for the formation of the shell and TEOS 341 
determines the hollow interior of the MSNPs 
75
.   342 
Synthesis of MSN yielded particle sizes of 216.5 ± 2.1 nm with a PDI of 0.13 ± 0.02 and a 343 
zeta-potential of -23.9 ± 0.4 (Figure 1A), similar to that reported by Fan et (180-185 nm). To 344 
confirm the particle size of the formulated MSNP, SEM imaging was used to assess the 345 
morphological structure of MSNP.  The nanoparticles developed demonstrated a uniform 346 
particle distribution of similar sizes and relatively uniform smooth particles and particle sizes 347 
of approximately 200 nm (Figure 1B and 1C).  348 
FT-IR assessment was also used to assess the removal of the template from the mesoporous 349 
materials and confirmed with four bands at 550, 1500, 2900 and 3000 cm 
-1
 before CTAB 350 
removal (Figure 2) corresponding to the CH2 and CH3 groups in CTAB molecule structure, 351 
which were eliminated after template removal (Figure 2).  352 
To determine the porosity of the MSNP and ascertain the pore volume and density, nitrogen 353 
adsorption/desorption isotherms were generated.  The nitrogen absorption-desorption 354 
isotherms identify the characterise hysteresis-type loop associated with capillary (pore) 355 
condensation at P/P0 > ≈ 0.2 (Figure 3A).  The hysteresis loop can be classified as a H1 loop, 356 
which is often associated with porous materials exhibiting a narrow distribution of relatively 357 
uniform (cylindrical-like) pores. The overall distribution of the pore radius was confirmed 358 
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through BJH analysis and demonstrated a narrow pore radius relative to the cumulative pore 359 
volume with the majority of the radius distribution, dV(r), located <20-30 Ang (< 10 nm).  360 
Furthermore, the pore width distribution confirmed a pore with distribution of < 4 nm (Figure 361 
3B and C) with a large surface area 987.67 ± 3.38 m
2
/g and the DFT method confirms that 362 
the average pore size of 1.93 ± 0.01 nm (Figure 3B and C) with total pore volume 0.95 ± 363 
0.004 cc/g and possessing similar porosity to other reported MSNP 
76, 77
.   364 
3.2 Phytochemical loading into MSNP 365 
The loading of curcumin into MSNP was confirmed through FT-IR analysis. The 366 
characteristic IR absorption frequencies in the spectral range of 550-4000 cm
-1
 were 367 
measured for free curcumin and Curc-MSNPs. The interaction between MSNPs and 368 
curcumin after being loading was also analysed using FTIR.   Curcumin spectra shows the 369 
following characteristic peaks: broad peak at 3420 cm
-1
 confirming the intermolecular 370 
hydrogen bonding in isolated silanol and enolic hydroxyl groups, with a broader shift when 371 
incorporated into MSNP indicating potential enhancement of hydrogen boding (Figure 4A). 372 
The signature peaks of curcumin are located at 1627 cm
-1 
and 1602 cm
-1 
and are attributed to 373 
the C═C double bonds and aromatic C═C double bonds, respectively 78 (Figure 4B). Finally 374 
bands at 1,279 cm
−1
 and 1,152 cm
−1
 were assigned to the aromatic C-O stretching and 375 
stretching in the C-O-C 
78
 (Figure 4B) 
79, 80
.  In all cases, these bands were absent in the blank 376 
MSNP.  For chrysin, the FT-IR spectrum shows bands at 2921 cm
−1
, 2710 cm
−1
  and 2631 377 
cm
−1
  for stretching in the C-H and C=C (Figure 4C and D). Furthermore, carbonyl group 378 
vibrations coupled with the double band in the γ-benzopyrone ring at 1653 cm-1 and 379 
absorption bands at 1612, 1577 and 1450 cm
-1
 related to carbon vibration in benzene and γ -380 
pyrone rings (valance vibrations C=C) can be observed (Figure 4D) 
81
.  381 
To further characterise the loading of phytochemicals into MSNP, DSC thermographs were 382 
analysed for blank and loaded MSNP.  The thermograms of pure curcumin and chrysin show 383 
characteristic single melting endothermic peak at 176°C (Figure 5A) and 286 °C respectively 384 
(Figure 5B), which were absent in the loaded MSNP (Figure 5A). Furthermore, the absence 385 
of characteristic single melting endothermic peaks for loaded MSNP confirms the washing 386 
step in the ‘dry method’ had removed residual phytochemical adsorbed onto the surface of 387 
the MSNPs and secondly that the loaded phytochemical was present in the amorphous form.  388 
Furthermore, TGA analysis show that the total weight loss of the loaded MSNP at the end of 389 
the run was 22.16 ± 1.12 % compared to the blank MSNPs, 7.21 ± 0.45 % with a calculated 390 
LC of 14.95 ± 0.67 % and which corresponds to the calculated EE of 12.34 ± 1.28 % for the 391 
‘wet method’ for curcumin (Figure 5C).  For chrysin the total weight loss of the Fan-MSNP 392 
at the end of the run was 21.07 ± 0.75 % compared to the blank MSNPs, 9.58 ± 1.94 % with a 393 
calculated LC of 11.49 ± 1.19 % and which corresponds to the calculated EE of 12.34 ± 1.28 394 
% for the ‘wet method’ (Figure 5D). 395 
To confirm loading of curcumin into MSNP, particle size demonstrating an increase in the 396 
hydrodynamic mean diameter from 216.8 ± 2.1 nm to 263.51 ± 8.3 nm after loading with 397 
curcumin (P ≤ 0.01) with a statistically significant increase in the PDI from 0.13 ± 0.02 to 398 
0.26 ± 0.05 (P ≤ 0.05) (Figure 6A). Furthermore the zeta potential of the Curc-MSNP 399 
decreased from -23.9 ± 0.4 mV to -16.9 ± 0.9 mV (P ≤ 0.01) (Figure 6B).  This increase in 400 
particle size and PDI has been previously reported after loading curcumin in their 401 
mesoporous nanoparticles 
51, 79
.  Furthermore the decrease in zeta potential following loading 402 
has previously been reported, however the polarity of the resultant charge is a function of the 403 
pH of the media that the zeta potential is measured in, with reports that a lower pH media 404 
often leads to more positive zeta potential with loading 
82-85
. 405 
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Similarly for chrysin the hydrodynamic mean diameter increased from 216.8 ± 2.1 nm to 406 
283.5 ± 8.3 nm after loading (P ≤ 0.01) with a statistically significant increase in the PDI 407 
from 0.13 ± 0.02 to 0.31 ± 0.11 (P ≤ 0.05) (Figure 6C) and an associated decrease in zeta 408 
potential from -23.9 ± 0.4 mV to -30.8 ± 0.3 mV (P ≤ 0.01) (Figure 6D). However reports 409 
from other chrysin loaded nanoparticle systems indicate a negative zeta potential in the range 410 
we detected 
86, 87
. 411 
Traditionally the zeta potential has been considered an important element for cellular 412 
interaction, with positively charged NP being favoured over negatively charges NP due to the 413 
negative charge of a cell membrane 88. That said, a number of reports have identified that the 414 
zeta potential is less of an issue for MSNP due to their highly mesoporous nature 
89
 
90
.  415 
Furthermore the endosome escaping, “proton sponge” effect 91, may explain the ability of 416 
Fan-MSNP to undergo internalisation, considering negative charge, without any specific 417 
ligands for receptor mediated endocytosis. 418 
With TGA analysis some weight loss at low temperature may have been attributed to 419 
adsorbed water whereas the weight loss at higher temperatures can be attributed to loss of 420 
surface silanol groups. However, no significant weight loss was evident during the study and 421 
this implies Fan-MSNP were thermally stable 
92
. In the case of both chrysin and curcumin, 422 
the loaded nanoparticles demonstrated no characteristic melting point depression confirming 423 
the amorphous nature of the loaded phytochemical and confirming negligible drug adsorbed 424 
93
.  425 
3.3 Cellular toxicity towards olfactory cells  426 
To investigate the toxicity of MSNP, curcumin and chrysin towards OBGF400 cells a cell 427 
viability assay was conducted with phytochemicals/MSNP exposed to OBGF400 for 24 428 
hours.  For MSNP, cell viability was generally maintained across the concentration range of 429 
10-100 µg/mL (Figure 7A), with a statistically significant (P≤ 0.01) decrease in viability from 430 
100 µg/mL onwards.  For curcumin (Figure 7B) and chrysin (Figure 7C), cell viability was 431 
maintained across the concentration range of 0.001-10 µM and an IC50 of 33 ± 0.18 µM was 432 
determined for curcumin.  For chrysin at 100 µM, a statistically significant (P ≤ 0.01) 433 
decrease in cell viability was observed (to 58.2 ± 8.5 %).  Reports of toxicity of MSNP with 434 
olfactory cells have not been reported by others but contradictory reports comment on 435 
relationships between the particle size and cellular toxicity, which appears to be cell line 436 
specific.  For example, smaller-sized silica nanoparticles induced severe cellular damage in 437 
lung cancer cells, myocardial cells, and human endothelial cells 
94-96
 and this was thought to 438 
be related to the fact that smaller nanoparticles have larger ratio of surface area to weight and 439 
therefore potentially more contact with the cells to induce damage 
97-99
.  However others have 440 
reported that larger silica nanoparticles are more cytotoxic than smaller particles on human 441 
hepatoma cells 
100
.   442 
All MTT assays were conducted in cell culture media containing serum.  A possible 443 
explanation for the conflicting reports in cellular toxicity associated with MSNP (and NP 444 
more generally) may be associated with a protein corona that is formed on the surface of 445 
silica nanoparticles that may alter the cytotoxic potential of the nanoparticles when in contact 446 
with serum proteins from tissue culture media 
101, 102
 . 447 
No other reports are available of the cellular toxicity of curcumin or chysin with OBGF400 448 
cells, however others have reported similar IC50 in CNS related cell lines (porcine brain 449 
microvascular endothelial cells PBMEC/C1-2: 63 ± 1.2 µM) 
23
. Similar IC50 values have been 450 
reported for curcumin, 15.2 μM and 16.4 μM against A2780CP and MDA-MB-231 cells 451 
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respectively 
74
.   Mukerjee and Vishwanatha 
103
 found the IC50 of curcumin loaded PLGA 452 
nanoparticle was 31µM for PWR 1E cells as compared to 37µM of free curcumin 453 
Any foreign particle to be taken up by the cell is dependent upon many factors such as size, 454 
charge, affinity etc. It has been reported that nanoparticles smaller than 100 nm could cause 455 
unspecific cellular uptake and cytotoxicity 
104
. Silica nanoparticles in the size range of 50-300 456 
nm are capable of inducing endocytosis 
105
 without causing any cytotoxicity and they have 457 
been reported to possess high affinity to many phospholipids present on the surface of the 458 
cell, which may even induce pinocytosis 
106
. 459 
To assess the morphological alteration of cellular structures when exposed to MSNP, Curc-460 
MSNP and Chry-MSNP, a gas and humidity controlled phase contrast imaging study was 461 
conducted using the CellIQ
®
 imaging system.  OBGF400 cells, grown in wells of a 6-well 462 
plates, were exposed to 50-150 µg/mL of MSNP, Curc-MSNP and Chry-MSNP for 40 hours 463 
with images captures within a defined window within each well every 15 minutes using live-464 
cell imaging.  The impact of MSNP on cell viability/proliferation at 150 µL/mL demonstrate 465 
a clear impact on the viability and proliferation of OBGF400 over 40 hours resulting in a 466 
reduction in the cell morphological volume and cell death. This effect was diminished at a 467 
concentration of 50 µg/mL, where cell morphology was maintained throughout the 468 
incubation period (See supplementary materials figure 2) 469 
With Chry-MSNP, a similar impact on cell viability was noted at 150 µg/mL. However, at 50 470 
µg/mL cell morphology was seen to change associated with the apoptosis of some cells (See 471 
supplementary materials figure 3). For Curc-MSNP, cell morphology was noted to alter at 472 
150 µg/mL leading to an increase in cell death over time, however at 50 µg/mL cell viability 473 
was not affected and proliferation of cells was noted (See supplementary materials figure 4). 474 
3.4 Cellular uptake of nanoparticles into olfactory cells 475 
A key goal for our studies was to demonstrate uptake of MSNP into olfactory bulb neuronal 476 
cells.  To assess this process fluorescent latex beads of 100 nm and 500 nm size ranges were 477 
selected to allow cellular imaging of the intracellular localisation of beads, providing some 478 
insight into appropriate size ranges for viable cellular uptake. For 100 nm sized latex beads 479 
the cellular localisation of the beads is evident, particularly in the membrane regions and 480 
cytoplasm (Figure 8). For the 500 nm sized latex beads a x63 magnification was used to 481 
enlarge isolated OBGF400 cells with membrane localisation and partial cytoplasmic trapping 482 
observed (Figure 8). 483 
The fluorescent molecule FITC was subsequently passively loaded into MSNP resulting in an 484 
EE of 48 ± 2.3 % and the release of FITC was assessed in PBS (pH 7.4) media (See 485 
supplementary materials).  The duration of the release study was set at 2 hours, primarily as a 486 
result of the short exposure-time expected with nasally delivered formulation coupled with 487 
the limited duration with which cell cultures can proliferate in the absence of growth media.  488 
Minimal FITC was identified as having been released from FITC-MSNP, 4.8 ± 0.19 %, over 489 
a 2-hour period suggesting the relative stability of the FITC molecule within the MSNP 490 
structure (see supplementary materials Figure 1). 491 
To further discern the exact localisation of MSNP within the cell, FITC loaded MSNP were 492 
prepared and incubated with OBGF400 cells before z-stack confocal microscopy was used to 493 
capture FITC- MSNP fluorescence through the z-dimension of the cell The confocal stage 494 
was set at the upper-most boundary of the OBGF 400 cells and the stage moved down 495 
towards the coverslip with images captured over a z-dimension of approximately 5 µm. At 496 
the onset of the z-stack analysis, FITC-MSNP is localised on the exterior of the cell boundary 497 
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and potentially on the surface of the cells (10763 µm).  As the stage progresses, the 498 
localisation of FITC-MSNP increases with clear demarked zones of cytoplasmic localisation 499 
near the ‘mid-to-bottom’ regions of the cells (Figure 9).500 
However, cellular uptake of both sizes of beads were detected using confocal microscopy and 501 
suggest MNSP formulation over this size range would be appropriate for olfactory uptake.  502 
Although the use of fluorescent latex beads as retrograde transport markers for neuronal 503 
pathways is not new 
107-109
, the application to olfactory bulb neuronal cells is novel indicates 504 
the potential for nano-sized material to penetrate into this class of cells. 505 
MSNP possessing a negative zeta potential have been previously reported 
110-112 
and 506 
associated with successful cellular uptake for both naïve MSNP and modified MSNP.  The 507 
uptake of MSNP in our study is presumed to be through a nonspecific pathway as the use of 508 
naïve MSNP incorporated no surface functionalisation for cellular targeting.  Furthermore, 509 
the location of clarithin coated vesicles on olfactory and the reported uptake of MSNP via 510 
clathrin-dependent endocytotic pathways due to their siliceous composition, and unique 511 
hexagonal exterior and internal hexagonal mesopores
113 
would indicated this would be the 512 
favoured uptake route of otherwise electronically unfavourable interactions between MSNP 513 
and the cell membrane. Furthermore, the it has been reported that nanoparticles possess a 514 
negative zeta potential illicit a “proton sponge” effect within the endosome whereby the 515 
negative zeta potential MSNP would aid  in buffering the internal charge of the endosome, 516 
resulting in an increase in osmotic pressure (due to Cl- influx) and swelling and finally 517 
facilitating endosomal escape through rupturing
91
. 518 
 519 
3.5 Phytochemical release study from the mesoporous silica nanoparticles 520 
The release of curcumin from Curc-MSNP was assessed over 24 hours and demonstrated a 521 
pH sensitive release phenomena. A burst effect was also evident after 1 hour with 12 % and 522 
16.6 % released at pH 7.4 and pH 5.5 respectively (Figure 10A).   Release at pH 7.4 was 523 
slower than that at pH 5.5, with 16.1 ± 1.6 % released at 24 hours (P ≤ 0.001).  At pH 5.5 524 
release increased over 24 hours to 53.2 % ± 2.2 % (P ≤ 0.001).  However, no significant 525 
increase in curcumin release was observed from 1 hour to 24 hours. 526 
The release of chrysin from Chry-MSNP was assessed over 24 hours and also demonstrated a 527 
pH sensitive release phenomena. A burst effect was evident after 1 hour with 3.2 ± 1.2 % and 528 
7.1 ± 1.6 % released at pH 7.4 and pH 5.5 respectively (Figure 10B).   Release at pH 5.5 was 529 
slower than that for pH 7.4 (P ≤ 0.001), with 9.4 ± 0.6 % and 16.8 ± 0.8 % at 24 hours 530 
respectively. However statistically significant differences (P ≤ 0.001) were also observed 531 
between 1 hour and 24 hours release at each pH studied. Furthermore, the release profile for 532 
both phytochemicals demonstrated a burst effect at early time points and this pattern has also 533 
been reported elsewhere 
114-117
.  This may be a result of the rapid dissolution of the loaded 534 
phytochemicals closer to the exterior of the pores with slower penetration of solvent into the 535 
pores as a result of the micro/meso size pores of < 2 nm . 536 
The differences in release of curcumin from mesoporous nanoparticles at difference pHs is 537 
important as the release in the nasal cavity (pH 5.5) is likely to be more rapid.  Furthermore, 538 
it has been reported that curcumin is relatively unstable at pH 7.4 compared to more acidic 539 
pH, which may explain the lack of increase in cumulative release from 1 hour to 24 hours 540 
(~1.8 %) compared to the ~36% increase in cumulative release at pH 5.5 at 24 hours 
117-119
.  541 
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The degradation has been reported to be complex but at a pH < 1, curcumin exists in the 542 
protonated form (H4A
+
), with increasing pH the neutral form (H3A) predominates.  543 
Furthermore stability in acidic conditions is likely due to its conjugated diene structure which 544 
becomes gradually destroyed as the proton is removed during the dissociation of the phenolic 545 
groups within the structure of curcumin (H2A
−
, HA
2−
 and A
3−
) which occurs at higher pHs 546 
and is likely the cause of curcumin being significantly more prone to degradation 
120, 118
.  An 547 
analysis of the HPLC chromatograms for curcumin at 1 hour and 24 hour also confirms 548 
differences in peak ratios suggesting degradation of curcumin at pH 7.4 rather than pH 5.5 549 
(See supplementary materials figure 5).   550 
Therefore at nasal pH (~5.5) both curcumin and chrysin loaded MSNP would be expected to 551 
be relatively stable at physiological pH and undergo release from the MSNP.   552 
The difference in cumulative release between phytochemicals may be related to the pore size.  553 
The pore size influences the potential loading capacity (and therefore potentially the release 554 
pattern) from MSNP 
106,121
.  Furthermore, the penetration of the phytochemicals within the 555 
naïve (non-functionalised) pores of MSNP would largely therefore depend on the molecular 556 
properties of the loaded phytochemicals.  557 
Curcumin posses a larger molecular weight (368.38 g/mol) and 3 distinct molecular entities: 558 
two aromatic ring systems containing o-methoxy phenolic groups, connected with a seven 559 
carbon linker consisting of an α,β-unsaturated β-diketone structure with the diketo group 560 
exhibiting keto-enol tautomerism. Chrysin (254.23 g/mol) on the other hand belongs to the 561 
flavone group of phytochemicals and consists of A and C rings, and a phenyl B ring attached 562 
to position 2 of the C ring, thus essentially three pi-pi conjugated rings.  As a result of the 563 
narrow pore width, the difference in release rates may be a function of the ability of curcumin 564 
to diffuse from within the porous structure more rapidly (due to steric hindrances) compared 565 
to chrysin. Furthermore chrysin possess planar stereochemistry and the pi-pi structure would 566 
enhance the non-covalent bonding interactions within the pores, resulting in a slower release 567 
profile. 568 
 569 
4. CONCLUSION 570 
Age related neurological disorders such as Parkinson’s disease (PD) and Alzheimer’s disease 571 
(AD), are insidious progressive neurological disorders which are expected to increase in 572 
incidence over the next century. Current approaches to CNS drug delivery are often 573 
hampered by poor targeting and drug delivery to the BBB and nose-to-brain delivery, 574 
following olfactory targeting, provides a promising novel way to bypass the BBB.  575 
We have developed phytochemical-loaded MSNP and have systemically investigated the 576 
loading, uptake and in-vitro release of phytochemicals from MSNP.  Our studies have 577 
demonstrated that nanoparticles below 500 nm would be capable of being taken up by 578 
olfactory cells and that the release of phytochemicals from MSNP is pH dependant, 579 
potentially suited to the slightly acidic nature of the nasal cavity. 580 
Although the successful intranasal delivery of the formulation onto the olfactory mucosa may 581 
significantly enhance its eventual delivery to the brain, we believe that the present study 582 
demonstrates the benefits of MSNP as a drug carrier and particularly in its applications 583 
towards nose-to-brain delivery of phytochemical loaded nano-carriers. 584 
 585 
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LIST OF FIGURES 953 
Figure 1: MSNP particle sizing. (A) DLS particle size and PDI; (B) SEM image wide angle 954 
view; (C) SEM image 60000x magnification. 955 
 956 
Figure 2: FT-IR spectra of MSNP prior to CTAB removal (red) and immediately after CTAB 957 
removal (black). CTAB and MSNP bands are indicated. 958 
 959 
Figure 3: Surface porosity assessment of MSNP. (A) Nitrogen adsorption/desorption 960 
isotherms of MSNP; (B) BJH pore radius distribution of MSNP. The Barrett Joyner-Halenda 961 
pore sizes (Å: Ang) were calculated based on assessment of the cumulative pore volume (y-962 
axis) (red line) with the region corresponding to a pore diameter of 1-4 nm indicated by the 963 
shaded box; (C) BJH pore width distribution of MSNP. The pore width (nm) were calculated 964 
based on assessment of the cumulative pore volume.  STP: standard temperature and 965 
pressure. 966 
 967 
Figure 4: FT-IR spectra of (A) Curcumin; (B) Curcumin loaded MSNP (Curc-MSNP).  968 
(C) Chrysin; (D) Chyrsin loaded MSNP (Chry-MSNP). 969 
 970 
Figure 5: DSC thermogram of (A) curcumin and (B) chrysin as native drug (red) and MSNP 971 
loaded (green).  TGA thermograms (C) curcumin and (D) chrysin as native drug (red) and 972 
MSNP loaded (green). 973 
 974 
Figure 6: MSNP particle size and PDI before and after loading with curcumin (A and B) and 975 
chrysin (C and D).  Statistical significance tested between unloaded and loaded MSNP. * P≤ 976 
0.05, ** P≤ 0.01. 977 
 978 
Figure 7: Cellular toxicity of (A) MSNPs, (B) Curcumin and (C) Chrysin on OBGF 400 979 
cells. Cells were grown on a 96-well plate at a density of 10 x103 cells per well and exposed 980 
to various concentrations of MSNP (10 – 1000 µg/mL) or phytochemicals (0.001-100 µM) . 981 
After 24 hour incubation 100 µL MTT in PBS (0.5mg/mL) added to each well & incubated 982 
for 4 hours. The MTT-formazan produced was solubilised in DMSO and quantified 983 
colorimetrically using a UV-spectrophotometer at 570 nm.  The control cell (without drug) 984 
corresponded to a cell viability of 100%. Data is reported as mean ±SD with up to 8 985 
replicates per compound in at least 3 independent experiment. ** P ≤ 0.01. 986 
 987 
Figure 8: Confocal microscopy of latex bead uptake in OBGF400:  A concentration of 0.1 % 988 
v/v of latex beads (100 nm and 500 nm) were dispersed into HEPES (25mM) buffered HBSS 989 
prior to the addition into wells containing OBGF 400 cells grown on collagen coated 990 
coverslips.  Beads were incubated for 2 hours before the coverslip were washed, fixed and 991 
mounted onto coverslips with mounting media.  Confocal microscopy was used to visualize 992 
the cellular localisation of beads with a 40x (100 nm) or x63 (500 nm) oil immersion 993 
objective. All images were acquired using an argon laser at 494 nm to visualise the beads and 994 
a helium laser to visualise DAPI at 461 nm.  995 
 996 
Figure 9: z-stack confocal microscopy of FITC-MSNP: FITC-MSNP previously incubated 997 
with OBGF 400 cells for 2 hours were further subjected to a z-stack analysis with the lens 998 
positioned above the cell layer (10763 µm) and lowered through the cells to the bottom of the 999 
cell layer (10758.4 µm).  Individual images were captured of FITC (green) and DAPI (blue) 1000 
through the z-dimension. 1001 
25 
 
Figure 10: Cumulative percentage release of (A) curcumin and (B) chrysin from MSNP.  The 1002 
in vitro release was performed in 154 mM PBS pH 7.4 and pH 5.5 containing 0.1 % Tween 1003 
80. 1 mg/mL of phytochemical loaded MSNP were dispersed into 2 mL of release medium, 1004 
briefly sonicated and placed in a shaking incubator maintained at 37 ˚C and 100 rpm. 1005 
Samples were withdrawn at set time intervals and the volume replaced with an equal volume 1006 
of pre-warmed release medium. Release was assessed through HPLC-UV methods. N=3.  # # 1007 
# indicates statistical comparison between the final time point (24 hours) and the first time 1008 
point for (1 hour) for pH 5.5 with a P ≤ 0.001. *** indicates statistical comparison between 1009 
the final time point (24 hours) between pH 5.5 and 7.4 with a P ≤ 0.001 1010 
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